Metformin

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial

Monday, September 13, 2021 - 7:00am

There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.

Key Points: 
  • There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.
  • Platform trials, such as those used to test fluvoxamine, allow multiple therapies to be tested using a single study design with a shared control arm.
  • Dr. Wathen is well known for his work in platform trials having helped design several platform trials previously and his contributions and help in designing the I-SPY 2 trial, a platform trial that transformed breast cancer research.
  • The TOGETHER TRIAL may also open the door for platform trials to become a much more widespread research study design.

Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Friday, September 10, 2021 - 6:00am

TWYMEEG is Poxels first product to reach commercialization and Japan is the first country where the product has been approved.

Key Points: 
  • TWYMEEG is Poxels first product to reach commercialization and Japan is the first country where the product has been approved.
  • Poxel has received a milestone payment of JPY1.75 billion (EUR13.2 million, USD15.8 million)2 from Sumitomo in July for the approval of TWYMEEG.
  • TWYMEEG is a first-in-class drug with a unique dual mechanism of action for the treatment of type 2 diabetes across the continuum of the current treatment paradigm.
  • TWYMEEG (Imeglimin), Poxels first-in-class lead product that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.

Global $64.95 Bn Antidiabetic Drug Markets, 2021-2026 by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis - ResearchAndMarkets.com

Wednesday, August 25, 2021 - 3:54pm

The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.

Key Points: 
  • The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.
  • According to the International Diabetes Foundation, diabetes affects one in every five persons aged 65 and up throughout the world.
  • However, an important factor restraining the antidiabetics drug market is the decrease in treatment and drug efficacy over time, which can lead to various health issues.
  • In addition, the high cost of medicines is seen as a challenge for the growth of the global antidiabetic drug market.

Hua Medicine Announces 2020 Interim Results

Thursday, August 19, 2021 - 9:31am

SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").

Key Points: 
  • SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").
  • In the first half of 2021, Hua Medicine reached a breakthrough milestone in preparing for dorzagliatin's commercialization.
  • In anticipation of dorzagliatin commercialization, subject to approval of its NDA, in addition to its CMO partnerships, Hua Medicine has also established Hua Medicine drug manufacture company at Shanghai Lingang Special Area for ensuring adequate dorzagliatin commercial supply.
  • This article contains the statements regarding the future expectation, plan and prospects for Hua Medicine and the investigational product.

Theralogix’s Remplir Targets Drug-Induced Nutrient Depletion of Magnesium and Vitamin B12

Tuesday, July 6, 2021 - 2:08pm

To counter the long-term effects of this drug-induced nutrient depletion (DND), Theralogix has developed a nutritional supplement called Remplir to replenish vitamin B12 and magnesium levels.

Key Points: 
  • To counter the long-term effects of this drug-induced nutrient depletion (DND), Theralogix has developed a nutritional supplement called Remplir to replenish vitamin B12 and magnesium levels.
  • Scientific evidence shows that these medications reduce serum vitamin B12 concentration by inhibiting the absorption of the vitamin.
  • Remplir is a unique formulation that combines two forms of vitamin B12 methylcobalamin and cyanocobalamin along with chelated magnesium, designed to provide optimal absorption and bioavailability.
  • Vitamin B12 and magnesium supplementation is essential for anyone using PPIs or metformin on an ongoing basis, said Ratner.

Liraglutide And Insulin More Effective In Maintaining Average Blood Glucose Levels Than Other Common Diabetes Drugs

Monday, June 28, 2021 - 11:55pm

It was designed to compare the effectiveness of glucose-lowering medications in maintaining average blood glucose levels in the target range that has been identified to reduce the risk of long-term complications.

Key Points: 
  • It was designed to compare the effectiveness of glucose-lowering medications in maintaining average blood glucose levels in the target range that has been identified to reduce the risk of long-term complications.
  • Medications in addition to metformin, which is recommended by the ADA for initial use to treat type 2 diabetes, are often needed to treat type 2 diabetes to help lowerA1C levels.
  • The study enrolled more than 5,000 patients with type 2 diabetes with an average age of 57 years and an average duration of diabetes of four years.
  • Results of GRADE demonstrated that liraglutide and insulin were the most effective of the four medications in keeping A1C levels less than 7%.

Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease

Thursday, June 10, 2021 - 2:00pm

Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.

Key Points: 
  • Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.
  • Without metformin, T2D patients with advanced CKD often require high doses of insulin to achieve glucose control, which can increase the risk of severe hypoglycemia.
  • Based on recent evidence that metformins glucose-lowering effects are largely attributed to direct action at the gut wall, Anji is developing a gut-targeted metformin for use in T2D patients with kidney disease.
  • Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients as efficiently as possible.

Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation

Thursday, April 15, 2021 - 2:00pm

b'Anji Pharma has initiated dosing in the U.S. and China as part of a Phase 2 program for pradigastat (ANJ908) in functional constipation.

Key Points: 
  • b'Anji Pharma has initiated dosing in the U.S. and China as part of a Phase 2 program for pradigastat (ANJ908) in functional constipation.
  • In addition to functional constipation, related conditions where pradigastat may have clinical benefit include irritable bowel syndrome-associated and opioid-induced constipation.\n\xe2\x80\x9cDespite the prevalence of chronic constipation, current treatment options are desperately lacking, with low response rates typical for all approved medications,\xe2\x80\x9d said Dan Meyers, M.D., Chief Medical Officer of Anji.
  • Anji\xe2\x80\x99s Phase 2 study with pradigastat will enroll approximately 180 patients at clinical sites in U.S. and China.
  • In addition to pradigastat, Anji is developing delayed-release metformin (ANJ900) for effective glucose management in patients with type 2 diabetes and advanced chronic kidney disease.

University of Minnesota Medical School launches clinical trial studying metformin treatment for COVID-19

Monday, March 15, 2021 - 1:54pm

Minneapolis / St. Paul, March 15, 2021 (GLOBE NEWSWIRE) -- A new multi-site clinical trial led by the University of Minnesota Medical School is studying the effectiveness of metformin, a generic medication for type 2 diabetes, in the treatment of COVID-19.

Key Points: 
  • Minneapolis / St. Paul, March 15, 2021 (GLOBE NEWSWIRE) -- A new multi-site clinical trial led by the University of Minnesota Medical School is studying the effectiveness of metformin, a generic medication for type 2 diabetes, in the treatment of COVID-19.
  • It will be the first randomized clinical trial for COVID-19 in the world to include pregnant women.
  • The clinical trial launched after U of M Medical School researchers identified in computer modeling and observational studies that outpatient metformin use may decrease the likelihood of dying from or being hospitalized for COVID-19.
  • The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians.